Moving up the lines, AstraZeneca stakes another PhIII win for Lynparza as adjuvant breast cancer therapy

AstraZeneca and Merck are now fairly certain Lynparza works as an adjuvant therapy for BRCA-mutated high-risk HER2-negative early breast cancer.

That’s because the independent data monitoring committee for its Phase III OlympiA trial concluded that the PARP inhibitor crossed the superior boundary versus placebo for invasive disease-free survival — the main endpoint — and recommended that the companies stop the trial early and move to primary analysis now.